HealthPharma & Biotech

Neurotrope raising US$15.3mln to fund Alzheimer’s drug trial

It could be the first step in raising a total of around US$150mln and it will support a Phase 2b clinical trial

If all warrants were exercised Neurotrope would raise US$136mln on top of the initial US$15.3mln funding

Neurotrope (OTCMKTS:NTRP) told investors it is raising US$15.3mln to fund the clinical development of its potential Alzheimer’s drugs.

It is part of a series of share issues - via conversion of preferred stock and/or warrants – that could see more than US$100mln of additional funding for the group.

Cash raised will support a Phase 2b clinical trial, which will study 150 patients with moderately severe to severe Alzheimer's disease.

The company has an exclusive license to develop and commercialize bryostatin, which is described as a ‘potent modulator’ of an enzyme call protein kinase C epsilon (PKCe).

PKCe deficit is seen as a potential cause of Alzheimer’s disease. Neurotrope highlights that in animal research the activation of PKCe has shown to improve learning and memory. It also highlighted that PKCe has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders.

Initially, the company’s private placement will result in the raise of US$15.3mln with units sold to investors at 60 American cents each. Each unit will comprise one one-hundredth of a preference share (which can be converted later into common stock) and five separate share warrants.

If all warrants were exercised Neurotrope would raise US$136mln on top of the initial US$15.3mln funding.

Subscribers in the private placing will also be given the right to participate in any future equity financings over the next year.

Quick facts: Neurotrope

Price: $5.76

Market: NASDAQ
Market Cap: $75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

1 hour, 15 minutes ago

2 min read